Sanofi's subcutaneous, or under-the-skin, therapy helps prevent bleeding and lowers antithrombin, a protein that delays blood ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Perspective Therapeutics (CATX – Research ...

BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. Sell-side analysts expect that BioMarin Pharmaceutical Inc. will post 3.15 earnings per share for the current year.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investors in BioMarin Pharmaceutical Inc (Symbol: BMRN) saw new options become available this week, for the October 17th expiration. One of the key data points that goes into the price an option ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price target of $120.00. The company’s shares closed ...

BioMarin Pharmaceutical has a 1 year low of $60.63 and a 1 year high of $94.85. The company has a market capitalization of $13.45 billion, a P/E ratio of 32.05, a P/E/G ratio of 0.61 and a beta of ...